Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the colorectal cancer (CRC) drug market will be driven by the introduction of Sanofi-Synthelabo's Eloxatin in the United States, and the use of Pfizer's Camptosar, Aventis/Prasfarma/Yakult's Campto, and Eloxatin in the adjuvant setting. According to the new Pharmacor study entitled Colorectal Cancer, sales of these agents will almost double within the next 10 years. Combined sales of these agents will climb from almost $1.1 billion in 2002 to more than $2.1 billion in 2012, reflecting an annual growth rate of 7%.

The launch of premium-priced vascular endothelial growth factor (VEGF) inhibitors, and of epidermal growth factor receptor (EGFR) inhibitors, will further expand the market for CRC therapies; combined sales of these targeted agents will reach more than $1.6 billion in 2012.

"Experts interviewed by Decision Resources are enthusiastic about using adjuvant Camptosar and Eloxatin," said Mohamed Muhsin, analyst at Decision Resources. "However, their concern about these agents' toxicities will likely limit the compounds' use to high-risk, younger, fitter patients."

The study also finds that market expansion of Roche's Xeloda and launch of the COX-2 inhibitors for this indication (Pfizer's Celebrex and Merck & Co.'s Vioxx) will further expand the 2012 CRC market.

About Colorectal Cancer

CRC is the third most common form of cancer worldwide and the second leading cause of malignancy-related death in the United States. Although treatment options have increased over the last five years, the five-year survival rate for patients diagnosed with CRC remains poor; for those with distant metastases, the survival rate averages a dismal 5% in the seven major pharmaceutical countries under study (United States, France, Germany, Japan, Spain, Italy, and the United Kingdom). As such, there are significant opportunities for the development of new agents to impact the treatment of this disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Colorectal Cancer is an Onkos study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Non-Small-Cell Lung Cancer Drug Market to Exceed $4.1 Billion in 2012

View Now